

SymbioPharm and TargEDys enter an exclusive partnership to launch SymbioLife® Satyia® in Germany

Herborn, Longjumeau, November 29th, 2022. – TargEDys and SymbioPharm have signed an exclusive marketing and distribution agreement to launch SymbioLife® Satyia® in Germany. The novel dietary supplement based on the next generation probiotic *Hafnia alvei* HA4597® will be available from January 2023.

SymbioLife® Satyia® is a precision probiotic with a characterized mechanism of action at molecular level: It increases satiety thanks to the protein ClpB produced by the probiotic strain *Hafnia alvei* HA4597®. ClpB naturally mimics the human satiety hormone alpha-MSH. The improved feeling of satiety helps with successful weight loss, as confirmed by a clinical study with 230 overweight adults. This natural principle provided by SymbioLife® Satyia® is a new, natural, safe and effective weight management solution and has won multiple awards.

“We are extremely proud and excited about this new collaboration. SymbioPharm is in the top 3 of the German probiotics market and fathered one of the first probiotic pharmaceuticals globally”, **Gregory Lambert, CEO of TargEDys** says. “With the team’s knowledge of probiotic Enterobacteria, their strong position with doctors, pharmacies, and synergies with probiotics and diagnostics, they are the perfect partner for this premium, highly scientific product.”

“We are very excited to partner with TargEDys and work together on a new era of evidence-based probiotics. With the availability of the patent-protected probiotic *Hafnia alvei* HA4597®, the knowledge of its biological mechanism of action and the outstanding studies, we can now offer an effective solution for the growing problem areas of obesity and metabolic health” adds **Juergen Eck, Co-CEO and CTO of SymbioPharm**. “As pioneers in microbiome research and medical probiotics, we are proud to now also help shape the introduction of knowledge-based precision probiotics.”



[Picture](#) in high resolution

[Picture](#) in low resolution

Caption:

The new precision probiotic SymbioLife® Satyria® can improve the feeling of satiety and thus help with successful weight loss. ©SymbioPharm GmbH

About TargEDys

TargEDys® is a commercial-stage French biotech specialized in the development of nutraceutical solutions through microbiome interventions. The company is based on 15 years of research on the microbiota conducted within academic laboratories. TargEDys® develops a product portfolio focusing on overweight, undernutrition, and mental health, all based on the concept of PreciBiotic strains backed by a molecular mechanism of action and in vivo studies.

www.targedys.com

About SymbioPharm

SymbioPharm GmbH is a pioneer in microbiome research and knowledge-based probiotics - since 1954. Its mission is to preserve health and to heal diseases with probiotic bacteria – making use of the purely biological effect of natural occurring bacteria. Therefore, it researches the human microbiome and develops innovative microbiological therapy approaches. The company holds a state-of-the-art production facility, and with its 120 employees including in-house physicians, scientists and microbiological experts, showcases comprehensive expertise from diagnostics – with the Institute for Microecology – to solutions, with the ranges Symbioflor®, SymbioLact®, Symbiofem®, SymbioPet®, and now SymbioLife®.

www.symbiopharm.de

Contact:

SymbioPharm GmbH

Angelika Hecht

Public Relations

Phone: +49 (0)2772 981-350

eMail: angelika.hecht@symbio.de